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Resistance to antimalarial drugs has often threatened malaria elimination efforts and historically
has led to the short-term resurgence of malaria incidences and deaths. With concentrated malaria
eradication efforts currently underway, monitoring drug resistance in clinical settings comple-
mented by in vitro drug susceptibility assays and analysis of resistance markers, becomes critical
to the implementation of an effective antimalarial drug policy. Understanding of the factors, which
lead to the development and spread of drug resistance, is necessary to design optimal prevention
and treatment strategies. This review attempts to summarize the unique factors presented by
malarial parasites that lead to the emergence and spread of drug resistance, and gives an overview
of known resistance mechanisms to currently used antimalarial drugs.
 2011 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. The burden of drug resistance in malaria
Malaria, together with tuberculosis and HIV, is an important
cause of morbidity and mortality, especially among children
[1,2]. The disease is caused by the protozoan parasite Plasmodium,
and is transmitted by an Anopheline mosquito vector [3]. The ﬁve
Plasmodia species affecting humans are Plasmodium falciparum,
Plasmodium vivax, Plasmodium ovale, Plasmodium malariae, and
Plasmodium knowlesi, together causing approximately 225 million
incident infections per year, resulting in nearly one million deaths
[1,4]. Among them, P. falciparum is the most prevalent malaria spe-
cies worldwide, especially in Africa, causing the most severe form
of the disease and being responsible for over 90% of the deaths. P.
vivax is the second most common species, located mainly in Asia
and South America, and can cause a relapsing form of malaria [3,5].
The battle against malaria started with the discovery by Ross
and Grassi in 1898, showing that the transmission of malaria para-
sites occurs through the bite of an infected mosquito [6]. This ﬁnd-
ing formed the basis of initial malaria control measures, including
the installation of window and door screens and reduction of mos-
quito breeding sites through changes in agricultural habits and the
application of insecticides, namely dichloro-diphenyl-trichloroeth-chemical Societies. Published by E
. Lanzer).
I. Petersen), michael_lanzerane (DDT). These interventions functioned by limiting disease
transmission, and eliminated the disease from more than 10 coun-
tries between 1900 and 1946 [6]. In 1955, the World Health Orga-
nization launched the ‘‘Global Malaria Eradication Programme’’
and chloroquine chemotherapy was implemented to complement
the initial vector control measures. When the program was ofﬁ-
cially ended in 1969, an additional 27 countries were declared ma-
laria-free [6]. Unfortunately, elimination of malaria could not be
achieved in most underdeveloped countries (sub-Saharan Africa
was omitted from the original eradication program), resulting in
the current predominant distribution of malaria to sub-tropical
and tropical regions [1] (Fig. 1A). Among the reasons for the even-
tual halt to the eradication effort were widespread resistance to
available insecticides, wars and massive population movements,
difﬁculties in obtaining sustained funding from donor countries,
the lack of community participation, and ﬁnally, the emergence of
chloroquine resistant malaria in Southeast Asia and South America
around 1960 [7]. The subsequent spread of chloroquine resistant P.
falciparum to Africa and lack of an effective, affordable alternative
ultimately led to a 2- to 3-fold increase in malaria-related deaths
in the 1980s [8]. The only viable alternative to chloroquine, at that
time, was sulfadoxine–pyrimethamine, however, it also encoun-
tered drug-resistant parasites about a year after implementation
[9]. Several other antimalarial drugs have since been deployed to
combat parasites resistant to chloroquine and sulfadoxine–
pyrimethamine, including meﬂoquine, amodiaquine and quinine.lsevier B.V. All rights reserved.
Fig. 1. Efﬁcacy of selected antimalarial drugs and combination therapies in areas with malaria transmission. World map adapted from the World Health Organization
‘‘Malaria, countries or areas at risk of transmission, 2009’’ [147]. (A) Endemicity map showing the areas and countries where malaria transmission occurred in 2009. (B–E) The
graphic representation of the median percentages of treatment failure data collected from clinical trials with a minimum of 28 day of follow-up, published in the ‘‘Global
Report on Antimalarial Drug Efﬁcacy and Drug Resistance: 2000–2010’’ by the WHO [148]. (B) Chloroquine treatment failure; (C) amodiaquine treatment failure; (D)
sulfadoxine–pyrimethamine (Fansidar) treatment failure; (E) artemether–lumefantrine (Coartem) treatment failure. Please note that the scale in (E) differs from (A–D).
Abbreviations: CQ: chloroquine; AQ: amodiaquine; SP: sulfadoxine–pyrimethamine; AM: artemether (an artemisinin derivative); LM: lumefantrine.
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now similarly resulted in the selection of resistant parasites, at least
in some parts of the world. In 1998, another attempt to roll back
malaria was launched and has been relatively successful, with a
reduction in malaria-related mortality by about 20% from 985 000
in 2000 to 781 000 in 2009 [1]. The main pillars of the current ef-
forts have been vector control, including long-lasting insecticide
treated bed nets and indoor residual insecticide spraying (the
spraying of insecticides onto walls within dwellings), along with
improved diagnostics and usage of effective chemotherapy to treat
infected individuals, thereby curing the infection and reducing fur-
ther transmission [1]. Currently, the most effective treatment for
malaria are artemisinin-based combination therapies (ACTs) that
combine a semi-synthetic derivative of artemisinin, a chemical
compound isolated from the plant Artemisia annua, with a partner
drug of a distinct chemical class. ACTs compensate for the poor
pharmacokinetic properties of the artemisinins, increase treatment
efﬁcacy, and are thought to reduce the emergence of drug-resistant
parasites [10].
Unfortunately, recent alarming reports observed the emergence
of artemisinin resistant parasites in Southeast Asia, which could
derail the current elimination/eradication efforts, and again foster
an increase in malaria cases and deaths [11,12]. The emergence
and spread of drug resistance does not only lead to an increase
in treatment failures and mortality, but also augments the costs
associated with treatment and control efforts on the level of both
the affected individual (resulting from treatment, purchase of
bed nets and absenteeism from work) and the government (for
vector control, health facilities, education and research) [13].
In summary, the emergence of drug-resistant parasites severely
impairs control efforts and has to be contained or circumvented
with the use of alternative treatments. For this, a deeper knowl-
edge of regional drug resistance patterns, understanding of the
mechanisms of action of the currently used drugs, appreciation
of cross-resistance between drugs and elucidation of genetic mark-
ers for the surveillance of resistance are essential to rationally de-
sign an individualized effective drug policy in all malaria-affected
countries.2. Emergence and spread of drug resistance in malaria parasites
The emergence of resistance in Plasmodium depends on multi-
ple factors, including (i) the mutation rate of the parasite, (ii) the
ﬁtness costs associated with the resistance mutations, (iii) the
overall parasite load, (iv) the strength of drug selection, and (v)
the treatment compliance.
The mutation rate of the parasite has a direct inﬂuence on the
frequency at which resistance can emerge. While higher mutation
rates enable a faster emergence of resistance they can also lead to
an accumulation of deleterious mutations. In P. falciparum the
mutation rate was determined to be approximately 109 from
experiments measuring spontaneous mutations in the pfdhfr gene,
which is relatively low [14]. An increased mutation rate is advan-
tageous for the adaptation to quickly changing environments
[15]. This is exactly the situation that parasites are exposed to
upon changing drug selection pressures. Some studies describe
an ‘‘accelerated resistance to multiple drugs’’ (ARMD) phenotype,
present in isolates from Southeast Asia, which acquired drug resis-
tance at a higher rate than other geographically distinct strains in
in vitro experiments [16]. Such ARMD parasites could explain the
observation that resistance to new drugs often arises ﬁrst in South-
east Asia [16].
Since mutations associated with drug resistance often impart a
ﬁtness cost, the selective advantage acquired by becoming drug-
resistant is balanced by the biological cost arising from the alteredfunction of the mutated protein. Such a ﬁtness cost can be miti-
gated by the acquisition of compensatory mutations during pro-
longed drug pressure [17].
Additionally, it has been postulated that high parasitemias (P.
falciparum infections rise to 1010–1012 parasites within an individ-
ual) can lead to faster elimination of deleterious mutations and en-
hance selection of compensatory mutations [18].
The emergence of drug-resistant parasites can also be acceler-
ated by strong drug selection pressure, which decreases the prev-
alence of competing sensitive wild type parasites.
Inadequate drug exposure through improper dosing, poor phar-
macokinetic properties, fake drugs, or infections acquired during
the drug elimination phase of a prior antimalarial treatment can
all result in parasites exposed to sub-optimal drug concentrations,
which increases the probability for drug-resistant parasites to arise
[19]. In high-transmission regions, infections acquired after treat-
ment from a previous malaria episode are common and result in
the exposure of parasites to sub-therapeutic drug concentrations.
This, in turn, selects for drug-tolerant parasites, which may repre-
sent an intermediate stage to full resistance [20]. The time during
which sub-therapeutic concentrations are present within the pa-
tient is prolonged in antimalarials that possess a long half-life, a
drawback that is often balanced with the provided beneﬁcial pro-
phylactic effect this also imparts [21]. To mitigate the length of
time that drugs exist in sub-optimal concentration, treatment
guidelines should be strictly adhered to. However, this is a partic-
ular challenge in areas of high migration across borders, such as
along the Thailand–Burma border, and in areas of political or social
unrest, which disrupts prompt access to medical care and public
health measures, perpetuating the emergence and spread of resis-
tant parasites [22].
Transmission is another critical step for the spread of drug-
resistant parasites. The intensity of transmission has an important
role in determining if parasites are effectively transmitted during a
mosquito blood meal. Drug-resistant parasites emerging in a high-
transmission area would likely be present in a polyclonal infection
(up to 7 clones have been reported to coexist within one host [23]).
If mutations conferring drug resistance are associated with a sig-
niﬁcant ﬁtness cost, they are more likely to be outcompeted by
sensitive parasites and not transmitted efﬁciently. The spread of
resistant parasites is also affected by the impact of antimalarials
on the gametocytes, which are the transmissible stages of the par-
asite. Artemisinins have been shown to decrease the number of
gametocytes carried by a patient, thereby reducing transmission
[24]. In contrast, both sulfadoxine–pyrimethamine and chloro-
quine elevate the gametocytemia [25]. In addition, drug resistance
may enhance transmission if drug selection pressure diminishes
the viability of sensitive gametocytes in a polyclonal infection,
increasing the propensity for transmitting drug-resistant parasites
[26].3. Drugs used against malaria
Important attributes for the successful implementation of anti-
malarial drugs are good tolerability and safety (especially in young
children), affordability, availability in endemic countries and short
course regimens. Primarily to decrease the emergence of drug-
resistant parasites, almost all antimalarials are now to be adminis-
tered as part of a combination therapy, with each drug targeting
distinct mechanisms within the parasite.
3.1. Quinine
Quinine, an aryl-amino alcohol, is one of the oldest antimalarial
agents and has been used by the native population of Peru for
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treat fevers and chills. In 1820, the active alkaloid from the bark
was isolated and named quinine [27]. Synthesis, ﬁrst described in
1944, was complicated and availability issues during the world
wars prompted scientists to develop synthetic alternatives to qui-
nine, among them chloroquine, which eventually replaced quinine
for routine treatment [27]. Quinine is now used to treat severe
cases of malaria and, as a second line treatment, in combination
with antibiotics to treat resistant malaria. Its short half-life of 8–
10 h likely contributed to the scarcity of widespread quinine resis-
tance; however, several reports have indicated the emergence of
quinine resistance in vivo [28,29]. The molecular mechanism by
which quinine acts against P. falciparum is only partially under-
stood. Similar to chloroquine, quinine has been demonstrated to
accumulate in the parasite’s digestive vacuole (DV) and can inhibit
the detoxiﬁcation of heme, an essential process within the parasite
[30]. Recent studies show that the genetic basis for resistance to
quinine is complex, with multiple genes inﬂuencing susceptibility.
Currently, three genes have been associated with altered quinine
response: pfcrt (P. falciparum chloroquine resistance transporter),
pfmdr1 (P. falciparum multidrug resistance transporter 1), and pfnhe1
(P. falciparum sodium/proton exchanger 1), all of them encoding for
transporter proteins [31–34].
3.2. Chloroquine
Chloroquine is a 4-aminoquinoline that was introduced in the
late 1940s and used on a massive scale for malaria treatment
and prevention. Its efﬁcacy, affordability and safety, even during
pregnancy, made it the gold standard treatment of malaria for
many years [35]. Chloroquine has one of the longest half-lives
among antimalarials with approximately 60 days, which provides
a chemoprophylactic effect during the drug elimination phase
but also exposes the parasites to an extended time period after
which chloroquine has fallen below the therapeutic concentra-
tion, which may select for drug-resistant parasites [20]. Chloro-
quine resistant parasites emerged approximately 10 years after
its introduction, ﬁrst along the Thai–Cambodian border and also
in Colombia in the late 1950s [36]. Genetic epidemiological data
suggests that resistance then spread from Southeast Asia to Afri-
ca in the late 1970s. Additionally, resistance also emerged inde-
pendently from other foci, including Papua New Guinea and the
Philippines [36]. Chloroquine resistant P. falciparum is now pre-
dominant in nearly all malaria endemic regions (Fig. 1B), but de-
spite widespread resistance, chloroquine maintains some clinical
efﬁcacy in areas where patients have acquired partial immunity
to malaria (premunition), through repeated infections. This indi-
cates that even against resistant parasites chloroquine does
maintain some efﬁcacy, although not enough to solely clear
the infection [37]. Chloroquine is also the ﬁrst-line treatment
of P. vivax infections, however, the prevalence of chloroquine
resistant P. vivax is increasing [1].
Chloroquine’s mechanism of action has been an intense area of
research for decades and evidence supports that the principal tar-
get is the heme detoxiﬁcation pathway in the DV, where the para-
site degrades erythrocytic hemoglobin and polymerizes the
liberated toxic heme monomers to inert biocrystals of hemozoin
[38]. Chloroquine is a weak base with pKa values of 8.1 and 10.2
and therefore a proportion of the drug remains uncharged at the
neutral pH of the blood [39]. This allows chloroquine to diffuse
freely across membranes. However, when chloroquine encounters
the acidic DV, it becomes diprotonated and unable to transverse
across the membrane [39]. As it accumulates in the DV, chloro-
quine binds to hematin, a heme dimer [30]. This interaction pre-
vents the detoxiﬁcation of free heme, leading to the buildup of
heme monomers that permeabilize the membrane, resulting inthe eventual death of the parasite [40]. Polymorphisms in PfCRT
have been demonstrated to be the main chloroquine resistance
determinant [41]. In some parasite strains PfMDR1 can also modu-
late the degree of chloroquine resistance [42], indicating that some
alleles and overexpression of PfMDR1 may increase the concentra-
tion of chloroquine within the DV by active transport (Fig. 2A).
Interestingly, studies have demonstrated linkage disequilibrium
between PfMDR1 and PfCRT alleles in chloroquine resistant para-
sites in Southeast Asia and Africa, suggesting a functional interac-
tion of both proteins [26,43].
3.3. Amodiaquine
Amodiaquine, also a 4-aminoquinoline, is structurally related
to chloroquine and has been in use for more than 70 years
[20,44]. Amodiaquine has a short half-life of 3 h, thus the anti-
malarial activity is thought to be exerted by the primary metab-
olite, monodesethylamodiaquine, which has a half-life of 9–
18 days [20]. Based on structural similarity, amodiaquine is
hypothesized to act by inhibiting heme detoxiﬁcation, and has
been shown to accumulate within the DV and to bind to heme
in vitro [45,46]. Cross-resistance between chloroquine and amo-
diaquine has been reported and mutations in PfCRT and PfMDR1
are associated with decreased susceptibility to both drugs. How-
ever, cross-resistance is incomplete and some chloroquine resis-
tant parasites remain susceptible to amodiaquine (see below)
(Figs. 1C and 2A) [44].
3.4. Meﬂoquine
Meﬂoquine is a 4-methanolquinoline with a long half-life of 14–
18 days [20], which was ﬁrst introduced in the 1970s [47]. Resis-
tance to meﬂoquine is mediated by ampliﬁcation of pfmdr1, lead-
ing to overexpression of this resident DV membrane transporter
[48]. Although the exact mechanism of action remains unclear,
in vitro experiments demonstrate that meﬂoquine can bind to
heme and exert some antimalarial activity by inhibiting heme
detoxiﬁcation [49,50]. However, studies on transgenic parasites
expressing different pfmdr1 copy numbers, observed a reduced
parasite susceptibility to meﬂoquine with increased PfMDR1-med-
iated import into the DV [51,52], suggesting a primary mode of ac-
tion outside of the DV (Fig. 1B) [46]. Additionally, it has been
shown that meﬂoquine inhibits the import of other solutes into
the DV and might therefore also target the PfMDR1 transport func-
tion itself [51].
3.5. Piperaquine
The bis-4-aminoquinoline piperaquine possesses an extended
half-life of approximately 5 weeks. Due to structure similarities
with chloroquine, it has been postulated that piperaquine has a
similar mode of action to chloroquine. Although the exact mecha-
nism of action is unclear, studies have shown that piperaquine
accumulates in the DV and that it is a potent inhibitor of heme
polymerization [53,54]. In addition, electron microscopic studies
using a mouse malaria model, have revealed morphologic changes
of the DV and clumping of hemozoin in trophozoites after exposure
to piperaquine, further implicating the DV as a site of action
[55,56]. Intensive piperaquine monotherapy in China during the
late 1970s has led to the emergence of resistant P. falciparum
strains, resulting in the subsequent decline in its use. Piperaquine
was later ‘‘rediscovered’’ and is now employed as a partner drug in
an artemisinin-based combination therapy [56]. Modulation of
piperaquine susceptibility by mutations in PfCRT have been con-
ﬁrmed, however, the shift in piperaquine response was modest
[57], and the clinical relevance of this ﬁnding remains unclear.
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Lumefantrine (previously known as benﬂumetol) is structurally
related to the hydrophobic arylamino alcohol antimalarials. The
half-life of lumefantrine is about 3–5 days and absorption of this
lipophilic drug can vary between individuals [58], requiring the
co-ingestion with a high-fat meal to increase the oral bioavailabil-
ity [59]. Polymorphisms in PfMDR1, particularly the variant N86,
and ampliﬁcation of the encoding gene (pfmdr1) have been associ-
ated with reduced susceptibility to lumefantrine in Africa and Asia
[60–62]. Additionally, parasites with the wild type copy of PfCRT
show reduced susceptibility to lumefantrine, as indicated by both
ﬁeld studies and in vitro assays [63]. The inverse correlation be-
tween lumefantrine and chloroquine susceptibilities is quite inter-esting and may prove useful in regards to combination therapies
(Fig. 2C) [63].
3.7. Primaquine
Primaquine is an 8-aminoquinoline with a half-life of approxi-
mately 6 h [64] and is currently the only approved therapy for
the treatment of P. vivax hypnozoite liver stages [65]. Unfortu-
nately, primaquine is contraindicated in patients with certain sub-
classes of glucose-6-phosphate dehydrogenase (G6PD, encoded on
the X chromosome) deﬁciency, due to the risk of a severe reaction
resulting in hemolytic anemia. Prevalence of G6PD deﬁciency var-
ies in males in different endemic regions, with 0.9–28.1% in Africa,
0.7–10.8% in Southeast Asia, 6.1–29% in the Middle East and <2% in
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ine binds to PfCRT and can thereby inhibit chloroquine transport,
possibly leading to a synergistic action between the two antimala-
rials and a reversal of chloroquine resistance [67–69].
3.8. Atovaquone
Atovaquone is a lipophilic hydroxynaphthoquinone analog
structurally related to ubiquinol (an important coenzyme in the
electron transport chain within the mitochondria) and is used for
treatment of apicomplexan parasites, including Plasmodium, Toxo-
plasma, Theileria and Babesia [70]. It has a blood plasma half-life of
2–3 days [71,72]. Molecular evidence exists that atovaquone spe-
ciﬁcally targets the cytochrome bc1 complex, located in the inner
mitochondrial membrane, thereby inhibiting the respiratory chain.
In P. falciparum blood stage parasites the respiratory chain is re-
quired for the regeneration of ubiquinone, the electron acceptor
for dihydroorotate dehydrogenase, which is an essential enzyme
for pyrimidine biosynthesis [73]. Atovaquone is currently used in
combination with proguanil (Malarone), mainly as a prophylactic
medication for tourists, due to the high costs and easily arising
resistance, which is conferred by single nucleotide polymorphisms
in the cytochrome b gene [74].
3.9. Antifolate drugs
The antifolate drugs used for malaria therapy are the sulfa drugs
sulfadoxine and dapsone that inhibit the dihydropteroate synthe-
tase enzyme (PfDHPS), and pyrimethamine and proguanil, which
inhibit the dihydrofolate reductase (PfDHFR) activity of the bifunc-
tional dihydrofolate reductase/thymidylate synthase enzyme. In
addition to PfDHFR, proguanil may target other pathways [75].
The drug combination sulfadoxine–pyrimethamine (Fansidar),
which possesses a half-life of approximately 4–5 days, was intro-
duced in the 1970s after the emergence of parasites resistant to
chloroquine. Sulfadoxine–pyrimethamine was a highly effective,
cheap, well-tolerated drug combination with good complianceFig. 2. Hypothetical models for antimalarial drug transport pathways and drug target
determinants in resistance to several important antimalarial drugs. PfCRT and PfMDR1 re
organelle in modulation of drug susceptibility, possibly either by serving as a compartme
as a compartment, which harbors the target itself, and where the accumulation is limited
as a general drug efﬂux pump [121]. Parasite susceptibility states, inﬂuenced by variant
PfMDR1-ampliﬁed, PfCRT-K76/PfCRT-76T) to ﬁve antimalarial drugs (chloroquine, amo
deducted from the suggested drug accumulation sites, are depicted. (A) Chloroquine and a
demonstrate cross-resistance between them [149]. Therefore, a similar transport pathw
within the DV through passive diffusion, but may be increased through the activity of
Parasites obtain resistance to both drugs when PfCRT 76T present, which efﬂuxes both a
small variations in the strength of amodiaquine resistance depending on additional m
chloroquine [44]. The N86Y polymorphisms in PfMDR1 can further increase resistance
presumably aids active efﬂux, at least for chloroquine [121]. (B) The primary determinant
expression [42,48]. One mechanism of action for meﬂoquine resistance therefore might b
sequestration of the drug away from its hypothetical drug target located outside of the D
[51] also could lead to the hypothesis that meﬂoquine directly targets PfMDR1 function.
within the parasite. (C) There exist little data on the mechanistic target of lumefan
chloroquine and an inﬂuence of PfCRT and PfMDR1 haplotype and PfMDR1 copy number
ampliﬁcation both can lead to lumefantrine resistance [52,61]. Additionally, it has been s
follows similar patterns as suggested for chloroquine, amodiaquine and meﬂoquine, lum
resistant parasites and potentially additional transport pathways. Parasites that possess
transport of this mutated protein out of the DV. This suggests that the primary target of lu
PfMRP may be capable of actively transporting lumefantrine. (D) The drug targets of arte
activated by ferrous iron and subsequently alkylates molecules such as heme and speciﬁ
death [50]. Ferrous iron is present both in the DV as well as outside of the DV [151].
compartments. PfMDR1 ampliﬁcation leads to a weak but signiﬁcant decrease of arte
Additionally, a knock-out of PfMRP increases artemisinin susceptibility [121], indicatin
concentrations in the cytosolic compartment correlate with increased sensitivity, sugges
parasite’s survival than its action within the DV. Abbreviations: PfCRT: P. falciparum
transporter 1; PfMRP: P. falciparummultidrug resistance protein; CQ: chloroquine; AQ: am
KO: knock-out; RBC: red blood cell; P: parasite; DV: digestive vacuole.
3rates due to being administered in a single dose. Unfortunately,
resistance due to point mutations in both target enzymes emerged
quickly after introduction (Fig. 1D) [76]. Therefore, sulfadoxine–
pyrimethamine is now primarily used as intermittent preventative
malaria treatment during pregnancy and, to a lesser extent (due to
high prevalence of parasites resistant to the drug combination in
endemic regions), for the treatment of malaria infection. The two
other antifolate drugs, dapsone and proguanil, were also adminis-
tered as a combination, Lapdap. Unfortunately dapsone caused
hemolysis in G6PD deﬁcient patients, and therefore this combina-
tion therapy is no longer recommended [77].
3.10. Artemisinins
Since the emergence of resistance to almost all quinolone and
antifolate drugs in P. falciparum malaria, artemisinin and its deriv-
atives have been used as a replacement and now constitute the
linchpin in antimalarial chemotherapy worldwide. Artemisinin is
a natural product, isolated from the A. annua plant (Chinese worm-
wood) and has been used in China as an herbal remedy for many
centuries. Artemisinins have a unique trioxane structure with an
endoperoxide bond that is required for antimalarial activity [50].
Due to the low solubility of artemisinin, several semi-synthetic
derivatives are used clinically (artemether, artesunate, and
dihydroartemisinin) [78]. Among the current antimalarials, artem-
isinins have the shortest half-lives of 0.5–1.4 h [79]. Initial wide-
spread use of artemisinin derivatives as monotherapy in
Southeast Asia has likely contributed to the reduced efﬁcacy ob-
served in recent years along the Thai–Cambodian border, which
has been characterized as a delay in the parasite clearance time
(Fig. 1E) [11,50]. The mechanism of action of artemisinin drugs is
not fully understood, but the prevailing theory is that the endoper-
oxide bridge is cleaved, leading to the formation of reactive carbon
radicals that subsequently alkylate essential biomolecules [78].
Mutations in pfatp6 (P. falciparum Ca2+ transporting ATPase 6)
have been associated with decreased artemether susceptibility in
ﬁeld isolates from French Guyana [80] and polymorphisms inlocalization. The three transporter proteins PfCRT, PfMDR1 and PfMRP are major
side within the DV membrane [89,110], demonstrating the importance of this acidic
nt in which toxic drugs are sequestered away from their targets outside of the DV, or
by the transporters. PfMRP, located at the parasitic plasma membrane, possibly acts
s of the three transporters (PfMRP/PfMRP-KO, PfMDR1/PfMDR1-86N/PfMDR1-Y86/
diaquine, meﬂoquine, lumefantrine, and artemisinins) and the target localization,
modiaquine are structurally similar 4-aminoquinoline drugs and parasites generally
ay and drug target for both drugs is suggested. The majority of drug accumulates
PfMDR1, since susceptibility is increased in parasites overexpressing PfMDR1 [42].
ntimalarials out of the DV, the location of the drug target [102]. However, there are
utations in PfCRT (mainly in amino acids 72–75) while this is not the case for
[150], putatively decreasing the active transport into the DV. Additionally, PfMRP
conferring resistance to meﬂoquine is ampliﬁcation of pfmdr1, resulting in increased
e that overexpression of PfMDR1 leads to accumulation of meﬂoquine in the DV and
V. Alternatively, the observation that meﬂoquine inhibits PfMDR1 transport activity
PfMRP acts as a general drug efﬂux pump, reducing the concentration of meﬂoquine
trine. However, current evidence demonstrates an inverse cross-resistance with
on lumefantrine susceptibility [63]. Wild type PfMDR1 haplotype (N86), and pfmdr1
hown that wild type PfCRT (K76) also decreases susceptibility [63]. If drug transport
efantrine accumulates in the DV through active PfMDR1 transport in lumefantrine
a mutated form of PfCRT (76T) may display increased susceptibility by the active
mefantrine is found in the cytosol or another parasite organelle. Although untested,
misinin and its derivatives remain elusive, but it was suggested that artemisinin is
c proteins, thereby disturbing the parasite’s metabolism and ultimately causing its
Therefore, artemisinin could be activated and alkylate heme and proteins in both
misinin susceptibility, suggesting an accumulation of artemisinin in the DV [83].
g that it acts as an artemisinin efﬂux transporter. From the current data, higher
ting that inactivation of cytosolic enzymes and proteins is more detrimental to the
chloroquine resistance transporter; PfMDR1: P. falciparum multidrug resistance
odiaquine; MQ: meﬂoquine; LM: lumefantrine; ART: artemisinin (and derivatives);
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increased artesunate resistance in the rodent malaria parasite Plas-
modium chabaudi [81]. However, these two candidates do not show
consistent association with parasites demonstrating an elongated
parasite clearance time, the currently described in vivo phenotype
of P. falciparum parasites with reduced artemisinin susceptibility
[82]. Although not mediating complete resistance to artemisinin
derivatives, pfmdr1 ampliﬁcation can signiﬁcantly reduce parasite
susceptibility [52,82,83]. Additionally, some of the observed clini-
cal phenotypes may be attributed to parasites entering a quiescent
state during the ring stage of intraerythrocytic development when
exposed to artemisinin derivatives, thereby avoiding drug selection
pressure [84]. Whatever mechanism is mediating the observed
clinical phenotype, recent genetic analysis has demonstrated that
the reduction in artemisinin susceptibility has a heritable compo-
nent [12].
To prolong the lifespan of artemisinin drugs by reducing the
emergence of drug-resistant parasites, artemisinin derivatives are
administered in combination with at least one other antimalarial
compound [85]. Current artemisinin-based combination therapies
include artemether–lumefantrine (Coartem, presently the
most commonly used ACT worldwide), artesunate–meﬂoquine,
artesunate–amodiaquine, artesunate–sulfadoxine–pyrimethamine,
dihydroartemisinin–piperaquine, and artesunate–pyronaridine [1].4. Drug resistance genes and resistance mechanisms
Efﬁcient drug treatment involves the targeting of an essential
biological process, which differs from or is non-existent in the host.
Plasmodium is highly adapted to its unique living environments
and many genes show little or no sequence similarity to other
genes encoding characterized proteins [86]. This creates a number
of putative drug targets; however, with little information to evalu-
ate the functionality or essential nature of these determinants, tar-
get validation becomes a challenge. Additionally, the ﬁeld is
hampered by scarce or inefﬁcient genetic tools for the analysis
and identiﬁcation of candidate genes in this haploid organism [87].
Linkage studies of three available genetic crosses, investigation
of ﬁeld isolates and examination of candidate genes have led to the
identiﬁcation of the following genes responsible for resistance to
the most important antimalarial drugs. These have been imple-
mented as molecular markers to screen for the emergence of resis-
tance and assess its spread, as a means to inform rational drug
policy decisions.
4.1. PfCRT
Intensive chloroquine chemotherapy has led to the emergence
of resistant P. falciparum strains. Analysis of the progeny from a ge-
netic cross between the chloroquine sensitive strain HB3 from
Honduras and Dd2, a chloroquine resistant strain from Indochina,
identiﬁed a 36 kb region on chromosome 7 responsible for chloro-
quine resistance [88]. Subsequent examination of the locus identi-
ﬁed the P. falciparum chloroquine resistance transporter gene
(pfcrt), encoding a transmembrane protein of 424 amino acids
and 48.6 kDa localized within the DV membrane (MAL7P1.27)
[89]. Thus far, no crystal structure is available and little is known
about the tertiary structure or native function of PfCRT. Bioinfor-
matic analysis has predicted PfCRT to be a member of the drug/
metabolite transporter family with 10 transmembrane domains
and both N- and C-termini facing the cytosolic side of the organelle
[90]. Homologs of PfCRT have been identiﬁed in several Plasmodia
species (P. vivax, Plasmodium yoelii, P. chabaudi, P. knowlesi, Plasmo-
dium berghei) and CRT-like proteins exist in non-related organisms
such as Cryptosporidium parvum, Dictyostelium discoideum, and Ara-bidopsis thaliana [90]. Attempts to genetically disrupt pfcrt have
failed [91], suggesting an essential function in the parasite. Under-
lining the important function of this transporter, mutant PfCRT
haplotypes in Africa and Asia have been shown to confer a ﬁtness
cost to the parasite, although the strength of the ﬁtness cost varies
between strains from different regions [92–94]. Natural substrates
of other members of the drug/metabolite transporters include ami-
no acids, weak bases and organic cations [90]. Additionally, it has
been shown that CRT homologs in A. thaliana transport glutathione.
Similar physiological activities could be imagined for PfCRT
[95,96].
Several biochemical studies of the parasitic DV, comparing par-
asites expressing a mutant or a wild type pfcrt allele, demonstrated
that chloroquine accumulates within the DV and that parasites
with mutant PfCRT accumulate less chloroquine than parasites
expressing wild type PfCRT [97,98]. The most plausible explanation
for this difference in accumulation is that chloroquine resistant
parasites can export chloroquine via active transport [99,100].
Interestingly, by heterologous expression of pfcrt variants in Xeno-
pus oocytes and D. discoideum, it has been shown that mutant
PfCRT is involved in chloroquine transport while wild type PfCRT
is not [39,101]. Wild type and mutant PfCRT might therefore have
different drug transport properties.
The involvement of pfcrt polymorphisms in chloroquine resis-
tance, in particular the K76T mutation, was established by drug
susceptibility experiments (testing parasite strains that were
manipulated by allelic exchange and harbored different pfcrt
alleles [41,102]), and further validated as a strong marker for
predicting chloroquine treatment response [103,104]. Combining
bioinformatic structure predictions with both biochemical and cell
assay data supports the hypothesis that the K76T mutation is lo-
cated within the ﬁrst predicted transmembrane spanning domain.
This confers chloroquine resistance by exchanging a positively
charged residue with an uncharged amino acid, which could allow
the active efﬂux of diprotonated chloroquine out of the DV [90].
Parasites harboring the K76T mutation possess at least three addi-
tional mutations within the gene, which possibly compensate for a
loss of function caused by the initial K76T mutation. These muta-
tions manifest as a wide variety of PfCRT haplotypes, potentially
ﬁne-tuning transport activity and/or speciﬁcity. At least 19 addi-
tional polymorphic residues have been identiﬁed in chloroquine-
resistant clinical isolates and parasites subjected to selective drug
pressure in vitro [105]. PfCRT haplotypes also inﬂuence suscepti-
bility to other antimalarial drugs, including amodiaquine, quinine
and lumefantrine [63,104,106]. While amodiaquine and quinine
show cross-resistance with chloroquine, mediated primarily by
76T, lumefantrine displays an inverse cross-resistance, with the
wild type K76 leading to a reduced susceptibility to lumefantrine.
Additionally, it has been suggested that the speciﬁc haplotype of
amino acids 72–76 further modiﬁes the strength of resistance to
amodiaquine [44]. The PfCRT K76T polymorphism is a validated
marker for chloroquine resistance in the ﬁeld and should also be
considered as an indicator for amodiaquine resistance.
It has also been shown, that PfCRT is phosphorylated at the res-
idues S33, S411 and T416. Phosphorylation of these amino acids
plays an important role in trafﬁcking PfCRT to the DV, which might
have additional roles in regulating the transport activity or speci-
ﬁcity of the protein [107].
4.2. PfMDR1
The P. falciparum multidrug resistance transporter 1 (pfmdr1)
was originally identiﬁed by a candidate gene approach in an at-
tempt to identify the determinant of chloroquine resistance
searching for the homolog of the multidrug resistance (MDR)
transporter family, which is associated with drug resistance in
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5, encodes an ATP-binding cassette (ABC) protein of 1419 amino
acid and 162 kDa (PFE1150w), which consists of 12 membrane-
spanning helices with N- and C-termini predicted to extrude into
the cytosol [108,109]. It has been demonstrated that PfMDR1 re-
sides, like PfCRT, within the membrane of the DV [110].
The endogenous function of MDR-like proteins in other organ-
isms consists of the translocation of a variety of substrates includ-
ing sugars, amino acids, peptides, proteins, metals, inorganic ions,
toxins and antibiotics across cellular membranes [111]. Mutations
in MDR transporters in mammalian cancer cells lead to a decreased
intracellular drug accumulation, increased drug efﬂux, and cross-
resistance to structurally unrelated drugs. The MDR phenotype is
often mediated by gene ampliﬁcation, resulting in overexpression
of the protein [111].
PfMDR1 has been shown to import the ﬂuorophore Fluo-4 into
the parasitic DV [51], mediated by a functional ATP-binding cas-
sette [112]. Therefore, PfMDR1 might act as a general importer,
functioning to sequester toxic metabolites and drugs into the DV.
It might also indirectly inﬂuence drug ﬂux by affecting intracellular
ion gradients, such as chloride ions, or pH [113]. Functional expres-
sion studies of PfMDR1 in Xenopus laevis oocytes have shown that
this protein transports antimalarial drugs, with wild type PfMDR1
transporting quinine and chloroquine but not halofantrine; in con-
trast, mutant PfMDR1 transports halofantrine but not quinine or
chloroquine [114].
From analysis of ﬁeld isolates, ﬁve amino acid positions (86, 184,
1034, 1042 and 1246) have been reported to inﬂuence susceptibil-
ities to lumefantrine, artemisinin, quinine,meﬂoquine, halofantrine
and chloroquine [31,61,115,116]. Additionally, ampliﬁcation of
PfMDR1 is associated with reduced susceptibility to lumefantrine,
artemisinin, quinine, meﬂoquine, and halofantrine [52,117] and
deampliﬁcation of PfMDR1 leads to an increase in chloroquine
resistance [42]. Interestingly, ampliﬁcation of pfmdr1 also confers
a ﬁtness cost to the parasite in in vitro culturing experiments
[117,118].
Additionally, evidence suggests that PfMDR1 is phosphorylated
[119]. Mammalian MDR transporter homologs, when phosphory-
lated display altered transport activity [119]. Thus, the phosphory-
lation status of PfMDR1 could produce a similar alteration of
transport.
4.3. PfMRP
The multidrug resistance-associated protein (PfMRP) belongs,
like PfMDR1, to the family of ATP-binding cassette (ABC) proteins.
More speciﬁcally, it belongs to the ABC transporter C subfamily,
with members in other organisms known to transport anions like
glutathione (GSH), glucoronate, sulfate conjugates, and various
drugs [120]. Pfmrp, located on chromosome 1, encodes an 1822
amino acid protein of 214 kDa, which localizes to the plasma mem-
brane and membrane-bound vesicles within the parasite in asexual
and sexual erythrocytic stages (PFA0590w) [120,121]. The protein
is not essential in the blood stages, but genetic disruption leads to
increased parasite susceptibility to several antimalarial drugs like
chloroquine, quinine, artemisinin, piperaquine and primaquine
and accumulates more GSH, chloroquine and quinine [121]. Addi-
tionally, the lack of expression of PfMRP leads to a ﬁtness cost of
the parasite in in vitro culture at parasitemias above 5%, which
might be due to a an impaired transport of toxic compounds out
of the parasite. There is some evidence from linkage studies based
on in vitro drug susceptibility assays with ﬁeld isolates that point
mutations (Y191H and A437S) reduce susceptibility to chloroquine
and quinine [122]. In summary, PfMRP modiﬁes drug responses
but is not a major determinant in resistance to the currently used
drugs and it was hypothesized that PfMRP acts, possibly in concertwith other transporters, to efﬂux drugs and other metabolites out
of the parasite [121].
4.4. PfNHE
The P. falciparum Na+/H+ exchanger (pfnhe) is a candidate gene
within a locus on chromosome 13 that was identiﬁed during a
search for loci associated with quinine resistance in the progeny
of the Dd2  HB3 genetic cross [123]. PfNHE is a 1920 amino acids
protein with an approximate molecular mass of 226 kDa
(PF13_0019) and is predicted to have 12 transmembrane domains
and to be localized to the parasitic plasma membrane [124]. The
function of PfNHE has not been fully determined, but it is specu-
lated that it actively efﬂuxes protons to maintain a pH of 7.4 within
the parasite, countering acidiﬁcation by anaerobic glycolysis, the
parasite’s main source of energy [125]. PfNHE contains three
microsatellite regions and the increase of DNNND repeat number
in microsatellite ms4670 has been associated with decreased qui-
nine susceptibility, as demonstrated in some studies [126,127] but
not in others [29,128]. The inconsistent results concerning the
association of PfNHE mutations with quinine resistance indicate
either another gene in close physical proximity of pfnhe being
responsible for the reduction in quinine susceptibility or PfNHE
requiring other additional genetic factors for mediating quinine
resistance. Because of this, the DNNND repeat number may be a
valid marker for quinine resistance in some genetic backgrounds,
but not others.
4.5. Folate pathway
The folate pathway is a potent drug target in rapidly prolifer-
ating cells, like cancer cells and microorganisms. Resulting from
this observation, drugs targeting this pathway in Plasmodium
have been applied very successfully until the emergence of resis-
tant parasites. The folate pathway provides the parasite with
cofactors that are essential for the production of pyrimidines
for DNA replication and the metabolism of several amino acids.
Two enzymes, dihydropteroate synthase (PfDHPS, PF08_0095)
and dihydrofolate reductase activity of the bifunctional enzyme,
dihydrofolate reductase-thymidylate synthase (PfDHFR-TS,
PFD0830w) are currently targeted by antimalarial drugs. PfDHPS
is involved in producing a folate precursor and is inhibited by
the sulfur-based drugs sulfadoxine and dapsone. PfDHFR is
responsible for reducing dihydrofolate into tetrahydrofolate and
its function can be impaired by the action of the antifolate drugs
pyrimethamine and cycloguanil, the bio-activated metabolite of
proguanil [129]. Resistance to this safe and affordable combina-
tion therapy sulfadoxine–pyrimethamine (SP, also known as
Fansidar) has emerged in the late 1980s [130] and is now
wide-spread with point mutations in both pfdhfr and pfdhps
implicated in resistance. Important polymorphisms in PfDHFR,
conferring resistance to pyrimethamine, are 108D and 164L, with
51I and 59R further modulating the strength of resistance, in
addition to ampliﬁcation of PfDHFR [131–133]. Resistance to sul-
fadoxine is strongly associated with amino acids 437G and 581G,
with 436A, 540E, and 613S having enhancing effects [133]. Some
evidence exists that mutations in PfDHFR also might confer a ﬁt-
ness cost to the parasite [134].
4.6. Cytochrome bc1 complex
The cytochrome bc1 complex catalyzes the transfer of electrons
from ubiquinol to cytochrome c, which is coupled to the transloca-
tion of protons across the inner mitochondrial membrane, thereby
maintaining the membrane potential of mitochondria used to
produce ATP by an ATP synthase [135]. The antimalarial drug
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causing a collapse in the mitochondrial membrane potential, which
is lethal for the parasite [135]. Several mutations within the cyto-
chromeb gene (cytb,mal_mito_3) can lead to atovaquone resistance,
with most mutations altering the ubiquinol binding site of the pro-
tein [74,136]. This site is highly conserved across phyla. Studieswith
yeast and transgenic parasites support the theory that atovaquone
binds to the ubiquinol binding site, thereby disrupting the electron
transfer chain [73,137,138]. It has been hypothesized that in the
absence of atovaquonedrug pressure themutations in the ubiquinol
binding sitesmight confer aﬁtness cost to theparasite [135]. Indeed,
a double mutation in this conserved protein (M133I and G280D)
results in 5–9% ﬁtness cost according to cell culture experiments
[138].5. Drug resistance in P. vivax
Despite causing an estimated 72–80 million malaria infections
yearly, P. vivax has not received as much public and scientiﬁc
attention as P. falciparum [5]. One of the main reasons for this is
that P. vivax usually produces less severe symptoms. Nevertheless,
P. vivax leads to a disabling disease that can be fatal, and exacts a
similar economic burden as falciparum malaria. Additionally,
severity of the disease caused by P. vivax recently is increasing in
some parts of the world and the development of drug resistance
could result in an expansion of this debilitating and sometimes
deadly infection [139].
To assess drug resistance in P. vivax in the ﬁeld, results from
clinical studies and a limited number of laboratory studies using
modiﬁed drug susceptibility assays, which are recommended by
the WHO for P. falciparum, have been used [140].
The standard treatment for P. vivax infections consists of chloro-
quine for the treatment of the blood stages and primaquine to
eliminate the hypnozoites (or dormant liver stages) that can cause
disease relapses [1]. It is apparent now that chloroquine resistance
has emerged and is increasing in prevalence, especially in Papua
New Guinea and some parts of Indonesia, but there are also re-
ported cases of chloroquine resistant P. vivax in Southeast Asia,
South America and Africa [139]. For areas with chloroquine resis-
tant vivax malaria the WHO recommends treatment with ACTs,
which have proven to be effective also against P. vivax in several
clinical trials [1]. While chloroquine resistance arose 10 years after
its introduction, the cases of chloroquine resistance in P. vivaxwere
not reported until 30 years of usage in P. vivax treatment. It has
been hypothesized that the delay in the emergence of chloroquine
resistance is based on a more complicated multigenic mechanism
of resistance in P. vivax [141]. Another factor, which likely contrib-
uted to the delay in chloroquine resistance in P. vivax, is the sus-
ceptibility of P. vivax gametocytes to chloroquine, unlike those of
P. falciparum, which would decrease the transmission rate [141].
Also, evidence indicates that the immune system is more capable
of controlling P. vivax infections, thus reducing the disease burden
without the requirement for as much chemotherapeutic interven-
tion [141].
The search for drug resistance markers in P. vivax has been
based on the examination of the known resistance determinants
in P. falciparum. PvMDR1, the homolog of PfMDR1, has been dem-
onstrated to modulate chloroquine susceptibility [140,142,143]. Of
particular importance is the Y976F mutation, which is strongly
associated with resistance in the Western Paciﬁc regions. Unlike
in P. falciparum, the P. vivax ortholog of PfCRT, PvCRT, has not been
demonstrated to contribute signiﬁcantly to chloroquine resistance
(both sensitive and resistant vivax parasites carry K76), even with
high protein conservation and suspected performance of similar
biological functions [144].In areas where P. vivax and P. falciparum are co-endemic, ther-
apy is usually administered for the treatment of falciparum malar-
ia, either because of misdiagnosis or due to a diagnosed mixed
infection (in which case primaquine is also administered to treat
the P. vivax hypnozoite stage). This results in exposure of P. vivax
to additional antimalarial drugs, which likely exert some drug
selection pressure on P. vivax parasites. Indeed, mutations in the
ortholog enzymes targeted by sulfadoxine–pyrimethamine,
PvDHFR and PvDHPS, have been found in areas where P. falciparum
infections have been treated with this antifolate drug combination
[145]. In addition, in regions where meﬂoquine has been used for
the treatment of falciparum malaria, there is an increased preva-
lence of pvmdr1 copy number variation, suggesting that a similar
mechanism might decrease the susceptibility to meﬂoquine in
both Plasmodia species [143]. Also, preliminary evidence suggests
that altered susceptibility to artesunate is caused by mutations in
pvmdr1 and its ampliﬁcation status [143].6. Conclusion
With the emergence of drug resistance to the artemisinin deriv-
atives, often referred to as the last stronghold in malaria chemo-
therapeutical treatment, it is of critical importance to implement
antimalarial drug policies to contain, and hopefully curtail the
spread of resistance. Failure to do so would lead to a tragic setback
in the current efforts to eliminate malaria, and achieved reductions
in malaria-related morbidity and mortality.
Several drug regimen strategies can be applied to maximize
the lifespan of the currently used antimalarials, including the
use of multiple ﬁrst-line treatments, which would lead to vary-
ing drug selection pressure on local parasite populations, and
therefore decrease the emergence and spread of parasites resis-
tant to any one particular antimalarial [146]. One important ap-
proach that has already been employed is the use of
combination therapies, which decreases the selection of drug-
resistant parasites by the action of the partner drugs. Critical
to this strategy is the evaluation of preexisting resistance to
the partner drug used (or proposed) for any given region, since
most have been utilized previously as monotherapy, with the
notable exception of lumefantrine. One interesting strategy that
should be further investigated is the use of a combination of
drugs that exert opposing drug resistance pressures, for example
chloroquine and lumefantrine [63]. Adherence to the full treat-
ment regimen is essential to delay the emergence of drug-resis-
tant parasites and ensure adequate treatment of individual
infections. To address this, ACTs should be co-formulated to
make certain that all drugs in the combination are administered
simultaneously, along with public education and training of
community health workers to increase compliance. Another pre-
viously proposed strategy to extend the useful lifespan of the
limited antimalarial repertoire currently available is the reintro-
duction of drugs after the prevalence of resistant parasites has
waned. This approach is based on the assumption that drug-
resistant parasites would carry a ﬁtness cost, compared to sensi-
tive parasites, and would therefore be outcompeted without the
continued advantage during drug selection pressure [92]. This
would require that compensatory mutations had not already in-
creased the ﬁtness of the resistant parasites. The re-selection or
importation of drug-resistant parasites after re-implementation
of an antimalarial should therefore be vigilantly monitored.
Current tools, including long-lasting insecticide treated bed
nets, indoor residual spraying and effective, rapid case manage-
ment have clearly demonstrated a beneﬁt in the reduction ofmalar-
ia [1]. Full implementation of these, along with other transmission
interventions currently being developed (transmission blocking
1560 I. Petersen et al. / FEBS Letters 585 (2011) 1551–1562drugs or vaccines), can pare down the spread of drug resistance
after it has emerged. Combined with effective, rational drug treat-
ment policies, existing tools can further reduce malaria morbidity
and mortality worldwide to levels that have never been achieved.
This will, however, require sustained ﬁnancial and political support
and an understanding of the genetic mechanisms and pharmaco-
logical factors that impact treatment efﬁcacy, with a continuation
of efforts to monitor and address the emergence of drug-resistant
parasites. Together, these efforts will yield an important reduction
in the globalmalaria burden and provide a signiﬁcant beneﬁt to glo-
bal public health.
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